The Effects of Intrauterine Infusion of hCG at the Time of Embryo Transfer

Plain-language guide to NCT02668965: not phased randomized trial of hCG (human chorionic gonadotropin), 200 participants. Who took part, design and what was measured.

Key Facts

Registry ID: NCT02668965
Phase: not phased
Status: status unknown
Start: 2015-12
Completion (planned or actual): 2016-03
Participants: 200 (estimated)
Design: randomized, double-blind, health_services_research
Conditions studied: Infertility
Results posted: not yet

What This Study Did, in Plain Language

What Was Tested

In this not phased trial, researchers set out to test hCG (human chorionic gonadotropin).

It had two arms (groups): control (no intervention) and intrauterine hCG (experimental).

The registry classes the interventions as procedure.

More on the Plan

Patients at infertility clinic, siriraj hospital who come to start IVF/ICSI treatment cycle or endometrial preparation for embryo transfer are consiferes as eligible subjects.

Who Took Part

200 planned participants were the target.

It was open to women only aged from 18 years up to 43 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Infertile women aged 18-43 years. Indicated or willing for IVF/ICSI treatment or endometrial preparation for embryo transfer.

The full record lists 2 inclusion and 4 exclusion criteria; among the exclusions: azoospermic male partner; failure to retrieve oocyte after controlled ovarian hyperstimulation; no embryo retrieved for transfer.

How the Study Was Run

The set-up was randomized, parallel-group and double-blind.

The participants were allocated by chance, so the hCG (human chorionic gonadotropin) group and the comparison group should start out alike.

Groups ran in parallel: each of the participants stayed in one arm throughout.

As a double-blind hCG (human chorionic gonadotropin) study, the assignments were hidden from both participants and investigators until the end.

Those kept unaware of assignments: participant and care provider.

It started in 2015-12 with completion listed for 2016-03.

It ran at 1 site in Thailand.

Its stated primary purpose is health services research.

What Was Measured

Researchers chose this as the main measure: Clinical pregnancy rate (time frame: 2 weeks after positive serum beta-hCG).

It also tracked 2 secondary outcomes, for example Chemical pregnancy rate and Implantation rate.

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of hCG (human chorionic gonadotropin) in 200 people.

Its status is unknown; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the hCG (human chorionic gonadotropin) compound page, all human trials.

Our Notes on the Compound

hCG (human chorionic gonadotropin): An LH analog that drives Leydig-cell testosterone production.

hCG (human chorionic gonadotropin) in the library

Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.